1.14

0.87% -0.01

After Hours: 1.19 0.05 +4.39%

Adc Therapeutics Sa (ADCT)

Overview News Price History Option Chain Discussions Forecast

Adc Therapeutics Sa stock is traded at $1.14, with a volume of 785.48K. It is down -0.87% in the last 24 hours and up +11.76% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Previous Close:

$1.15

Open:

$1.18

24h Volume:

785.48K

Relative Volume:

0.44

Market Cap:

$145.00M

Revenue:

$79.18M

Net Income/Loss:

$-136.99M

P/E Ratio:

-1.0809

EPS:

-1.0547

Net Cash Flow:

$-120.11M

1W Performance:

-9.52%

1M Performance:

+11.76%

6M Performance:

-68.25%

1Y Performance:

-65.24%

1-Day Range:

$1.12

$1.21

1-Week Range:

$1.12

$1.30

52-Week Range:

$0.7796

$4.98

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name

Adc Therapeutics Sa

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

41 21 653 02 00

Address

BIOPOLE, EPALINGES

Employee

193

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

ADCT's Discussions on Twitter

Compare ADCT vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADCT Adc Therapeutics Sa	1.14	146.27M	79.18M	-136.99M	-120.11M	-1.0547
TAK Takeda Pharmaceutical Co Adr	17.44	55.06B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.94	43.07B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.08	35.88B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	76.92	31.59B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	527.94	26.32B	3.17B	1.29B	1.01B	27.09

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-06-22	Initiated	CapitalOne	Overweight
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-21	Initiated	Wolfe Research	Outperform
Aug-17-21	Resumed	Jefferies	Buy
Aug-09-21	Initiated	RBC Capital Mkts	Outperform
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight
Dec-03-20	Initiated	Stifel	Hold
Oct-29-20	Initiated	H.C. Wainwright	Buy
Jun-09-20	Initiated	BofA/Merrill	Buy
Jun-09-20	Initiated	Cowen	Outperform

View All

Adc Therapeutics Sa Stock (ADCT) Latest News

Jul 27, 2026

BlackRock (NYSE: BLK) discloses 5.4% ownership of ADC Therapeutics (ADCT) - Stock Titan

Jul 27, 2026

Orbimed Advisors LLC Has $4.94 Million Stock Position in ADC Therapeutics SA $ADCT - MarketBeat

Jul 27, 2026

TradingKey - TradingKey

Jul 27, 2026

ADCT|ADC Therapeutics SA|Price:1.145|Chg%:-0.005 - TradingKey

Jul 27, 2026

Jul 26, 2026